The world is closer than ever to ending HIV as a public health threat. As the global response to the HIV epidemic continues to transition from an emergency response to one focused on sustaining the progress we’ve made, it is critical that we continue to find innovative solutions to address new challenges.
Continue Reading
Expanding access to and uptake of PrEP products among young people, especially adolescent girls and young women, will be key to ending the HIV epidemic. But how do we ensure HIV prevention efforts resonate with and are effective for young millennials and Gen Z? What does meaningful youth engagement in PrEP delivery really mean?
Continue Reading
What sets CATALYST apart is the study’s emphasis on meaningful involvement of young people at every stage of the research to understand end-user perspectives and help tailor the study to meet their needs. This makes us hopeful because the inclusion of young people in the CATALYST journey has not been tokenistic; rather our contributions have been reflected in the whole process so far. In this post, we describe three ways youth have been engaged in CATALYST.
Continue Reading
We are excited to announce the launch of Catalyzing Access to New Prevention Products to Stop HIV (CATALYST), MOSAIC’s flagship product introduction study. CATALYST will provide and assess an enhanced service delivery package that includes oral PrEP, the PrEP ring, and injectable cabotegravir for PrEP.
Continue Reading
As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
CROI is a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases, including HIV and AIDS. It was the 30th year of the conference, but our first time attending. In this post, we reflect on what we learned and how we might apply key takeaways to our work on MOSAIC.
Continue Reading
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading
This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading
Sub-Saharan Africa is home to 25.3 million (67%) of the global total of 37.7 million people living with HIV infection (UNAIDS 2021). To control the epidemic in Africa, it is essential that solutions for Africa be generated and implemented in Africa.
Continue Reading
With the dapivirine vaginal ring and injectable cabotegravir poised to join oral pre-exposure prophylaxis (PrEP) as safe, effective HIV prevention products, people seeking an HIV prevention method that works for them will soon have real choices.
Continue Reading